Sign in
← Database
Bioregulator Peptide

Cartalax

Shop · Omnichems ↗Buy · Disguised Alpha ↗
Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

A short synthetic tripeptide (Ala-Glu-Asp) belonging to the Russian "peptide bioregulator" family; proposed mechanisms are largely theoretical and human clinical evidence is very limited.

How it works

Cartalax is a synthetic short-chain peptide — reported as the tripeptide alanine-glutamate-aspartate (AED) — that comes from a line of Russian research on so-called "peptide bioregulators." These are very small peptides claimed to influence the activity of specific tissues, with cartalax associated in that literature with cartilage and musculoskeletal tissue.

The general hypothesis behind this peptide family is that short peptides can enter cells, reach the nucleus, and influence gene expression in a tissue-selective way, nudging cells toward more "youthful" or balanced function. Cartalax specifically is discussed in the context of cartilage and connective tissue, and sometimes anti-inflammatory or regenerative effects.

Honesty about the evidence matters here: most supporting work originates from a small number of research groups and is preclinical or mechanistic, with limited independent replication and sparse rigorous human trial data. Cartalax is not an approved drug, and its marketed claims considerably outrun the strength of the published evidence. It should be regarded as experimental.

Mechanism · Detailed Analysis
Proposed molecular targetCartalax is described as a tripeptide bioregulator (Ala-Glu-Asp). The proposed mechanism in this peptide family is direct interaction with DNA or chromatin to modulate transcription of tissue-relevant genes, rather than binding a classical surface receptor. This gene-regulatory mechanism is hypothesized and not firmly established.
Signaling & downstream effectsIn the bioregulator framework, such peptides are claimed to normalize cell function in their associated tissue — for cartalax, connective/cartilage tissue — potentially affecting proliferation, differentiation, and inflammatory signaling. The concrete molecular pathways and the specificity of these effects are not well defined in independent, peer-reviewed human studies.
Evidence & development statusPublished support is dominated by a limited set of largely preclinical and in-vitro studies from a small research tradition; independent replication and well-controlled human clinical trials are lacking. Cartalax is sold as a research compound, not an approved therapeutic, and lacks established pharmacokinetic data.
CaveatsMechanistic claims should be read as theoretical. Purity, identity, and dosing of research-grade material are not standardized, and human safety data are minimal. Regenerative or anti-aging claims for cartalax are not supported by adequate clinical evidence.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.